YD Life Science

YD Life Science is a South Korean biotechnology company focused on the development of small molecule therapeutics for diabetic complications and oncology. The company's primary focus is on addressing unmet needs in ophthalmology, specifically through its lead candidate YD-312, an oral treatment for diabetic retinopathy currently in Phase 2 clinical trials. YD Life Science also maintains a pipeline targeting diabetic macular edema, diabetic nephropathy, and solid tumors. By developing oral alternatives to existing injectable therapies, the company seeks to improve patient compliance and quality of life for those suffering from chronic metabolic conditions.